Label Image (Lbl500901412)
Valsartan And Hydrochlorothiazide
Product Images NDC 50090-1422
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Valsartan And Hydrochlorothiazide (NDC 50090-1422). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Label Image (Lbl500901420)
Label Image (Lbl500901422)
Figure 1: Probability Of Achieving Systolic Blood Pressure <140 Mmhg At Week 8 (Valhyctz Fig1)
This text describes a study that assesses the effectiveness of a medication in reducing systolic blood pressure in individuals with hypertension. The medication, which contains a combination of Valsartan and Hydrochlorothiazide, is evaluated at a dosage of 320 mg /25 mg. The study includes a placebo group and the results are presented in a graph, which shows the probability of achieving a systolic blood pressure of less than 140 mmHg after 8 weeks of treatment.*
Figure 2: Probability Of Achieving Diastolic Blood Pressure <90 Mmhg At Week 8 (Valhyctz Fig2)
The text shows a graph (Figure 2) displaying the probability of achieving a diastolic blood pressure of less than 90 mmHg after 8 weeks. The graph includes three data points: 95, 100, and 105. Additionally, there is a baseline measurement of DBP shown to be less than 90 mmHg.*
Figure 3: Probability Of Achieving Systolic Blood Pressure <130 Mmhg At Week 8 (Valhyctz Fig3)
This is a graphic representation of the probability of achieving a systolic blood pressure of less than 130 mmHg at week 8 using a combination of Valsartan and Hydrochlorothiazide medication. The medication dosage is 320 mg/25 mg of Hydrochlorothiazide. The graph also shows the baseline systolic blood pressure range of 140-180 mmHg.*
Figure 4: Probability Of Achieving Diastolic Blood Pressure <80 Mmhg At Week 8 (Valhyctz Fig4)
This is a graph (Figure 4) that shows the probability of achieving a diastolic blood pressure of less than 80 mmHg after 8 weeks of treatment with Valsartan and Hydrochlorothiazide at a dosage of 320 mg and 25 mg respectively, compared to a placebo. The x-axis represents the baseline diastolic blood pressure while the y-axis represents the probability percentage. There are no readable characters to describe the text outside of the figure.*
Valsartan Chemical Structure (Valhyctz Str1)
Hydrochlorothiazide Chemical Structure (Valhyctz Str2)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
